The Manufacturers Life Insurance Company Acquires 80,926 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

The Manufacturers Life Insurance Company boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 18.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 513,328 shares of the company's stock after buying an additional 80,926 shares during the quarter. The Manufacturers Life Insurance Company's holdings in Teva Pharmaceutical Industries were worth $11,314,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TEVA. Oarsman Capital Inc. bought a new position in Teva Pharmaceutical Industries during the fourth quarter worth $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $44,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $50,000. Ameliora Wealth Management Ltd. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $66,000. Finally, IFP Advisors Inc boosted its stake in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after purchasing an additional 1,960 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Finally, Bank of America cut their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Up 8.8 %

Shares of NYSE:TEVA traded up $1.41 during trading on Wednesday, reaching $17.53. 24,302,064 shares of the stock were exchanged, compared to its average volume of 10,109,055. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The stock has a fifty day moving average of $15.09 and a two-hundred day moving average of $17.47. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm has a market cap of $19.88 billion, a price-to-earnings ratio of -12.09, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business's revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.48 EPS. Research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.